NEW YORK (
CHANGE IN RATINGS
downgraded at Jefferies to Hold from Buy, Jefferies said. $32 price target. Too much change to navigate comfortably.
(BBY - Get Report)
upgraded at Citigroup to Neutral from Sell, Citigroup said. $21 price target. More balanced risk/reward after 35% pullback.
Beneficial Mutual Bancorp
downgraded to hold at TheStreet Ratings.
Clean Energy Fuels
downgraded to sell at TheStreet Ratings.
downgraded at JMP from Outperform to Market Perform, JMP Securities said. Benlysta likely faces an uphill battle to gain adoption for doctors treating lupus.
rated new Hold at Cantor. $15 price target. Stock is already factoring in commercial revenue expected from Roche deal.
upgraded at McAdams from Sell to Hold, McAdams Wright Ragen said. Stock has pulled back to a fair value.
STOCK COMMENTS / EPS CHANGES
(BA - Get Report)
estimates lowered at UBS through 2013, UBS said. Gauging MAX impact on BCA margins. Neutral rating and $72 price target.
estimates, target reduced at Keybanc. CR estimates were cut through 2013, Keybanc said. Strong dollar and lower commecial demand could hurt near-term results. Buy rating and new $50 price target.
estimates lowered at Oppenheimer through 2013, Oppenheimer said. Impact of the PRC withholding tax. Outperform rating.
Discover Financial Services
numbers raised at Citigroup. Shares of DFS now seen reaching $35, Citigroup said. Estimates also increased to reflect better card credit. Neutral rating.
estimates, target raised at Credit Suisse. Shares of EFX now seen reaching $50, according to Credit Suisse. Estimates also increased, as the company can likely sustain solid organic sales growth, despite difficult macro conditions. Neutral rating.
(EW - Get Report)
target raised at Jefferies. Shares of EW now seen reaching $100, Jefferies said. Positive panel paves way for Sapien Label expansion. Buy rating.
Edwards Lifesciences target boosted at BMO. Shares of EW now seen reaching $94, according to BMO Capital. FDA panel was strongly in favor of approving Cohort A. Market Perform rating.
numbers cut at Citigroup. Shares of JBL now seen reaching $21, Citigroup said. Estimates also lowered given disappointing outlooks from major customers. Neutral rating.
(JCP - Get Report)
target cut at Morgan Stanley to $22, according to Morgan Stanley. Survey suggests a weaker consumer pricing environment. Underweight rating.